The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Open accessAbstract
PURPOSE: Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). METHODS: ARCHES (ClinicalTrials.gov identifier: NCT02677896 ) is a multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to enzalutamide (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume and prior docetaxel chemotherapy. The primary end point was radiographic progression-free survival. RESULTS: As of October 14, 2018, the risk of radiographic progression or death was significantly reduced with enzalutamide plus ADT versus placebo plus ADT (hazard ratio, 0.39; 95% CI, 0.30 to 0.50; P < .001; median not reached v 19.0 months). Similar significant improvements in radiographic progression-free survival were reported in prespecified subgroups on the basis of disease volume and prior docetaxel therapy. Enzalutamide plus ADT significantly reduced the risk of prostate-specific antigen progression, initiation of new antineoplastic therapy, first symptomatic skeletal event, castration resistance, and reduced risk of pain progression. More men achieved an undetectable prostate-specific antigen level and/or an objective response with enzalutamide plus ADT ( P < .001). Patients in both treatment groups reported a high baseline level of quality of life, which was maintained over time. Grade 3 or greater adverse events were reported in 24.3% of patients who received enzalutamide plus ADT versus 25.6% of patients who received placebo plus ADT, with no unexpected adverse events. CONCLUSION: Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamide in previous clinical trials in castration-resistant prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Self-citationDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationJames, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2706 · Cited by 1,518
Kyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Self-citationGravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., Kynaston, H., Gontero, P., Thalmann, G., Akdas, A., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.030 · Cited by 493
Gravis, G., Boher, J.-M., Joly, F., Soulié, M., Albiges, L., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.005 · Cited by 459
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., Dunshee, C., Wang, F., Wu, K., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9285 · Cited by 319
Self-citationShore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., van Os, S., Hasabou, N., Wang, F., Bhattacharya, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00518-5 · Cited by 278
Self-citationScher, H. I., Solo, K., Valant, J., Todd, M. B., & Mehra, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139440 · Cited by 238
Alumkal, J. J., Sun, D., Lu, E., Beer, T. M., THOMAS, G. V., Latour, E. J., Aggarwal, R. R., Cetnar, J. P., Ryan, C. J., Tabatabaei, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922207117 · Cited by 159
Morris, M. J., Molina, A., Small, E. J., Bono, J. S. D., Logothetis, C. J., Fizazi, K. S., SOUZA, P. D., Kantoff, P. W., Higano, C. S., Li, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3875 · Cited by 138
Halabi, S., Vogelzang, N. J., Ou, S., Owzar, K., Archer, L. E., & Small, E. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9159 · Cited by 113
TOMBAL, B. F., Fred Saad, C., Penson, D. F., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C., & Attard, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30898-2 · Cited by 109
TOMBAL, B. F., Borre, M., Rathenborg, P., Werbrouck, P., Poppel, H. V., Heidenreich, A., Iversen, P., Braeckman, J., Heráček, J., Baskin-Bey, E. S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70129-9 · Cited by 101
Cellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 101
Metastasis-free Survival — A New End Point in Prostate Cancer Trials
Beaver, J. A., Kluetz, P. G., & Pazdur, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1805966 · Cited by 78
Rajaram, P. S., Rivera, A., Muthima, K., Olveda, N., Muchalski, H., & Chen, Q. (2020) · Molecules · doi:10.3390/molecules25102448 · Cited by 68
Shore, N. D., Antonarakis, E. S., Cookson, M. S., Crawford, E. D., Morgans, A. K., Albala, D. M., Hafron, J. M., Harris, R. G., Saltzstein, D. R., Brown, G. A., et al. (2020) · The Prostate · doi:10.1002/pros.23967 · Cited by 67
Self-citationRathkopf, D. E., Beer, T. M., Loriot, Y., Higano, C. S., Armstrong, A. J., Sternberg, C. N., Bono, J. S. D., TOMBAL, B. F., Parli, T., Bhattacharya, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5808 · Cited by 62
Self-citationFizazi, K. S., Jenkins, C., & Tannock, I. F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv245 · Cited by 55
TOMBAL, B. F., Borre, M., Rathenborg, P., Werbrouck, P., Poppel, H. V., Heidenreich, A., Iversen, P., Braeckman, J., Heráček, J., Baskin-Bey, E. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.027 · Cited by 48
Self-citationPredicting survival in prostate cancer: the role of quality of life assessment
Braun, D. P., Gupta, D., & Staren, E. D. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1213-x · Cited by 46
Diagnostic characteristics of lethal prostate cancer
Helgstrand, J. T., Røder, M. A., Klemann, N., Toft, B. G., Brasso, K., Vainer, B., & Iversen, P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.007 · Cited by 46
Hall, M. E., Huelster, H. L., Luckenbaugh, A. N., Laviana, A. A., Keegan, K. A., Klaassen, Z. W. A., Moses, K. A., & Wallis, C. J. D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s228355 · Cited by 40
Tombal, B., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., Iversen, P., Braeckman, J., Heracek, J., Baron, B., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2017.08.103 · Cited by 26
Self-citationParker, D. C., & Cookson, M. S. (2020) · Korean journal of urology · doi:10.4111/icu.2020.61.s1.s3 · Cited by 5
Cited by
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119115 · Cited by 977
Self-citationGillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationProstate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 596
Metadata
- Authors
- Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., Rosbrook, B., Sugg, J., Baron, B., Chen, L., & Stenzl, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-11-10
- Volume
- 37
- Issue
- 32
- Pages
- 2974-2986
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2963794755
- Cited by
- 1,217
- References
- 38
- FWCI
- 82.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.